

Communication

A Simple and Expedient Procedure for the Preparation of Gabapentin Lactam (2-aza-spiro[4,5]decan-3-one)

Jashuva V P Katuri, Vadiraj S Ekkundi, and Kuppuswamy Nagarajan

Org. Process Res. Dev., **Just Accepted Manuscript** • DOI: 10.1021/acs.oprd.6b00246 • Publication Date (Web): 12 Sep 2016

Downloaded from <http://pubs.acs.org> on September 13, 2016

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



A Simple and Expedient Procedure for the Preparation of Gabapentin Lactam (2-aza-spiro[4,5]decan-3-one)

Jashuva V. P. Katuri,^{*b,c} Vadiraj S. Ekkundi^b and Kuppuswamy Nagarajan^{*a}

^aHikal Ltd, 3rd Floor, Grey Rock, No.10, 24th Main, J.P. Nagar 2nd Phase, Bangalore 560078, Karnataka, India.

^bHikal Ltd, 3A, International Biotech Park, Hinjewadi, Pune 411057, Maharashtra, India.


^cDepartment of Natural Product Chemistry, CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad 500007, Telangana, India.

AUTHOR EMAIL ADDRESS jashuva@iict.res.in, k_nagarajan@hikal.com


RECEIVED DATE (to be automatically inserted after your manuscript is accepted if required according to the journal that you are submitting your paper to)

TITLE RUNNING HEAD A Simple and Expedient Procedure for the Preparation of Gabapentin Lactam

TOC Graphic



Yields of gabapentin lactam with N-chloro reagents



ABSTRACT

1
2
3
4
5
6 A novel process has been described on 100 g scale for the preparation of gabapentin lactam which is a
7
8 penultimate intermediate for the preparation of gabapentin, comprising Hofmann reaction of 1,1-
9
10 cyclohexanediamic acid monoamide using chlorinating agents such as trichloroisocyanuric acid,
11
12 sodium dichloroisocyanurate, 1,3-dichloro-5,5-dimethylhydantoin and N-chlorosuccinimide, which
13
14 have not been employed so far for making this molecule. Reactions done in aqueous alkali on the 1,1-
15
16 cyclohexanediamic acid mono amide led to a solution of gabapentin sodium salt which on heating led
17
18 to the formation of the gabapentin lactam in good yield.
19
20
21
22

23 **KEYWORDS** Hofmann reaction, gabapentin, gabapentin lactam, trichloroisocyanuric acid, sodium
24
25 dichloroisocyanurate, 1,3-dichloro-5,5-dimethyl hydantoin, N-chlorosuccinimide.
26
27
28

INTRODUCTION

29
30
31 Gabapentin **1** is a therapeutically important drug in the treatment of certain forms of epilepsy, faintness
32
33 attacks, cranial traumas, hypokinesia and which additionally brings about an improvement on certain
34
35 cerebral functions.¹ Extensive and wide spread applications of gabapentin have given it a “blockbuster”
36
37 status. There are several processes available for the synthesis of **1** among which one using gabapentin
38
39 lactam **4** as a precursor is widely employed.² Lactam **4** by itself has interesting and potentially useful
40
41 biological activities, eg. it is a K⁺ channel activator and is neuroprotective,³ neurotrophic⁴ and enhances
42
43 new bone formation in vitro.⁵ Lactam **4** is also useful for the preparation of N-substituted
44
45 spiro lactams.^{2b} The first synthesis of **4** was reported by Sircar in 1928 by the Hofmann reaction of the
46
47 1,1-cyclohexanediamic acid monoamide **2** with alkaline sodium hypobromite at 55 °C for 2 h.⁶ The
48
49 reaction mixture was then acidified with HCl and evaporated to dryness. The residue was washed with
50
51 ether to remove free organic acids and extracted with acetone. The acetone extract was evaporated to
52
53 dryness. The residue was neutralized with alkali and extracted into ether. Evaporation of ether afforded
54
55 gabapentin lactam **4** in only 46% yield. This process is not useful for commercial production of **4**
56
57
58
59
60

1 because of the number of steps and the low yield of the desired product, making the process expensive
2 and unviable for commercial production of gabapentin **1** for which **4** is the crucial precursor. Later some
3 commercial processes for the preparation of gabapentin lactam **4** have been reported. Geibel et al.
4 disclosed the synthesis of lactam **4** from cyclohexanone in three steps⁷ - conversion of cyclohexanone
5 into ethyl cyclohexylidene acetate, followed by addition of nitromethane to form ethyl 1-
6 nitromethylcyclohexane acetate and finally catalytic reduction of the nitro ethyl derivative. In this
7 process hazardous nitromethane and costly Wittig reagents are used. In addition explosive and
8 inflammable hydrogen gas and pyrophoric catalyst such as 10% Pd-C are also employed. Steiner et al.
9 disclosed a synthesis of **4** from cyclohexanone in four steps⁸ - conversion of cyclohexanone into diethyl
10 cyclohexylidene malonate, addition of sodium cyanide to form diethyl 1-cyanocyclohexyl malonate,
11 hydrolysis of diethyl 1-cyanocyclohexyl malonate to 1-cyanocyclohexyl malonic acid and finally
12 catalytic hydrogenation of the cyclohexyl malonic acid at elevated temperature resulting in
13 decarboxylative lactamization. In this process the disadvantages are handling of highly poisonous
14 sodium cyanide and use of rhodium or pyrophoric Raney nickel as catalyst in the final step. Recently
15 we have reported a chemo-enzymatic process for making **4** from cyclohexanone.⁹ This method again
16 requires the use of highly poisonous sodium cyanide, explosive & inflammable hydrogen gas and use of
17 Raney nickel as catalyst. Alternatively **4** has been made from monoamide **2** using sodium
18 hypobromite.¹⁰ This process requires expensive and corrosive bromine for the preparation of sodium
19 hypobromite. Parsons and co-workers reported a new approach for the preparation of **4** on a small
20 scale,¹¹ wherein 1-cyclohexene-1-carboxaldehyde was condensed with benzoyl hydrazine to form the
21 corresponding hydrazone. This hydrazone was reduced with dimethylamine-borane/methane sulfonic
22 acid to get the hydrazine which was then N-acylated with trichloroacetyl chloride to give the
23 corresponding hydrazide. This was subjected to 5-exo-trig halogen atom transfer radical cyclization
24 mediated by copper (I) chloride and TMEDA (tetramethylethylenediamine) to form
25 trichlorospirolactam. Treatment of this trichlorospirolactam with wet Raney nickel gave **4**. This
26 procedure suffers from a few obvious draw backs such as number of chemical steps and scale up
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1 problems including chromatography. Hu and co-workers reported a transition metal catalyzed C-H
2 insertion reaction catalyzed by $\text{Rh}_2(\text{cap})_4$ to prepare N-tert-butyl gabapentin lactam.¹² This procedure is
3 handicapped by the use of expensive $\text{Rh}_2(\text{cap})_4$. Each of the above procedures suffers therefore from
4 various limitations. We hence felt that there was a genuine need for synthesizing **4** in higher yields and
5 of high purity at a low cost, which are commercial requirements so that the process can be used directly
6 for the production of gabapentin on large scale. In the present work chlorinating agents such as
7 trichloroisocyanuric acid, sodium dichloroisocyanurate, 1,3-dichloro-5,5-dimethylhydantoin and N-
8 chlorosuccinimide are reported for Hofmann reaction of 1,1-cyclohexanediactic acid monoamide to get
9 lactam **4** in good yields.
10
11
12
13
14
15
16
17
18
19
20
21
22

23 RESULTS AND DISCUSSION

24
25
26 1,1-Cyclohexanediactic acid monoamide **2** was prepared in high yield from commercially available
27 1,1-cyclohexanediactic acid by following the literature procedure.¹³ The use of chloro derivatives in
28 place of bromo derivatives in the Hofmann Reaction will make it economical from a cost perspective at
29 the production level.
30
31
32
33
34

35 As part of our work, initial experiments for the Hofmann reaction were performed using
36 trichloroisocyanuric acid (TCCA). TCCA has been widely applied in organic synthesis.¹⁴ It has been
37 used for the Hofmann reaction in methanol in order to get methyl carbamates¹⁵ but has not been utilized
38 for the synthesis of gabapentin. The advantages involved in the use of trichloroisocyanuric acid are i) it
39 is a solid having high melting point 246-247 °C, which can be handled easily ii) it is an inexpensive and
40 easily available reactant, iii) it can be used in the molar ratio of 0.33 to 1 of reagent to substrate iv) the
41 byproduct cyanuric acid can be recycled to make the starting material TCCA and this process can be
42 repeated for a number of times. In addition to this, a significant advantage in using TCCA is that it can
43 be stored at room temperature for many days unlike 10-15% sodium hypochlorite solution which has to
44 be prepared freshly before starting the reaction and has to be stored below 5 °C. Also since the volumes
45 of the reaction using TCCA are less compared to the common process using 10-15% sodium
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 hypochlorite process (~3 volumes less), batch throughputs can be usefully increased. Encouraged by the
2 above potential advantages, N-chlorination of 1,1-cyclohexanediactic acid monoamide **2** was
3 performed on its methanol solution with TCCA as described in the experimental section. The byproduct
4 cyanuric acid precipitated as solid. After disappearance of starting material **2**, as confirmed by TLC
5 analysis, the reaction mixture was filtered to remove the byproduct cyanuric acid which was obtained
6 quantitatively. The methanolic filtrate was evaporated to dryness using a rotary evaporator at 50 °C
7 under vacuum to get N-chloro cyclohexanediactic acid monoamide **3** as a solid in quantitative yield.
8 This hitherto unknown N-chloroamide, **3** was characterized completely by NMR and mass spectral
9 analysis. In ¹H-NMR (300 MHz, DMSO-d₆) a peak at 12.00 ppm showed the presence of –COOH
10 group. Proton resonating at 9.96 ppm showed the presence of –NH-Cl pattern. Protons resonating at
11 2.43 and 2.39 ppm showed the presence of two methylene groups as singlets. Multiplet seen in the
12 region 1.52 – 1.27 ppm represents the cyclohexyl group. In ¹³C-NMR (75 MHz, DMSO-d₆) carbonyl
13 carbons of acid and amide groups were seen at 172.9 & 169.3 ppm respectively. Methylene carbons
14 which are attached to carboxylic acid and amide groups were seen at 40.7 & 40.3 ppm respectively. The
15 signal of the quaternary carbon atom in the cyclohexyl group was seen at 35.1 ppm. The other five
16 carbons of cyclohexyl group were seen at 35.0, 25.5 and 20.9 ppm. The structure of the compound was
17 further confirmed by high resolution mass spectral analysis which showed the molecular ion peak at m/z
18 256 (M+Na). Thus the compound was unambiguously established to be N-chloro-1,1-
19 cyclohexanediactic acid monoamide **3**. This was subjected to the Hofmann Reaction by adding it
20 portion wise to aqueous sodium hydroxide solution at 0 – 5 °C over a period of 1 h. The resulting
21 reaction mass was processed as described in the experimental section. The solution containing the
22 sodium salt of gabapentin was subjected to cyclization under the experimental conditions to give lactam
23 **4** which was extracted by toluene. Evaporation of toluene at reduced pressure afforded **4** in 90% yield
24 with HPLC purity >99% (Scheme 1).
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Scheme 1 Hofmann reaction using TCCA

Although the above process gave lactam **4** in 90% yield it has a few limitations for use in production level such as, i) one isolation step involved (N-chlorination) including complete distillation of solvent and ii) obligatory use of methanol for keeping the monoamide in solution for N-chlorination. In order to overcome the above drawbacks, reactions were planned for using TCCA in water which is a green solvent and executed successfully. Accordingly, a solution of the sodium salt of 1,1-cyclohexanediamic acid monoamide, prepared by adding the monoamide **2** to excess 12% sodium hydroxide solution (4.4 equivalent of NaOH with respect to **2**; this excess NaOH is required for sodium salt formation of monoamide, Hofmann rearrangement including the liberated CO₂ quenching to Na₂CO₃) was added dropwise to a suspension of TCCA in water (1.5 V of water with respect to **2**) over a period of 1 h at 0-5 °C and the Hofmann reaction conducted under well defined conditions as described in the experimental section. Lactam **4** was obtained by evaporation of the toluene solution in vacuo in 75% yield with HPLC purity >98%. Cyanuric acid was recovered significantly from the TCCA reaction as described in the experimental section. To the best of our knowledge, trichloroisocyanuric acid has not been employed as chlorinating agent for making lactam **4** by Hofmann reaction. The generality of the method was extended to other chlorinating agents such as sodium dichloroisocyanurate (NaDCC), 1,3-dichloro-5,5-dimethylhydantoin (DCDMH) and N-chlorosuccinimide (NCS).





1 Sodium dichloroisocyanurate (NaDCC) is used widely for treating potable water, waste water, water
2 in swimming pools and many other industrial water systems.¹⁶ Benjamin Staskun reported the use of
3 NaDCC for the Hofmann degradation of 4-chlorobenzamide to 4-chloroaniline¹⁷ and also Pallavicini et
4 al. have reported for N-chlorination.¹⁸ Unlike trichloroisocyanuric acid, it is highly soluble in water (25
5 g in 100 mL water). We have examined its synthetic utility for making gabapentin lactam for the first
6 time under conditions given in the experimental section and were gratified to find that it proceeded very
7 well to afford **4** in 85% yield with HPLC purity >99%. Obviously the homogenous nature of reaction
8 mass using the solution of the sodium dichloroisocyanurate compared to the non-homogeneity in the
9 case of trichloroisocyanuric acid is the reason for the superior performance of the former reagent.
10 Cyanuric acid was recovered significantly from the sodium dichloroisocyanurate reaction as described
11 in the experimental section. These chloroisocyanuric acids are very interesting from the perspective of
12 green chemistry,¹⁹ as these are alternative reagents to generate organic compounds without using
13 hazardous chlorine gas every time as these reagents can be prepared in bulk and can be stored at room
14 temperature for long time and used on call.²⁰ They also have advantages from the atom economy point
15 of view, as they can transfer majority of their mass to the substrate, for example trichloroisocyanuric
16 acid can transfer up to 46% of its mass. They are not expensive and can be regenerated from recovered
17 cyanuric acid.

18 We have also examined the synthetic utility of 1,3-dichloro-5,5-dimethyl hydantoin (DCDMH) for
19 the Hofmann reaction in water. The reagent has been extensively used as a bleaching agent for
20 industrial and domestic water.²¹ Recently Zou et al. have reported the use of DCDMH for selective
21 preparation of α -mono and α,α -dichloro ketones.²² We have undertaken to study its synthetic utility for
22 Hofmann reaction in the present work. Following the standard procedure for gabapentin lactam **4**, using
23 DCDMH, **4** was obtained in only 55% yield with HPLC purity >99%. N-Chlorosuccinimide (NCS) has
24 been widely used as electrophilic chlorinating agent in organic synthesis.²³ NCS in water was used for
25 the synthesis of pregabalin.²⁴ In our hands, use of NCS for the Hofmann reaction of **2** afforded **4** in 46%
26 yield (Scheme 2).



10
11
12
13
14
15
16
17

Reagent (Equiv)	Gabalactam (4) yield (%)
TCCA (0.33)	75
NaDCC (0.55)	85
DCDMH (0.55)	55
NCS (1.1)	46



44
45

Scheme 2 Hofmann reaction using TCCA, NaDCC, DCDMH and NCS in water

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The quality of gabapentin lactam **4** is critical for the purity of derived gabapentin. HPLC data of lactam **4** obtained from these processes are listed in Table 1. Typical minor unknown impurities seen are at 0.74, 0.84 and 0.94 RRT and pleasingly, the levels are near nonsignificant. To the best of our knowledge there is no report available thus far in the literature for the use of TCCA, NaDCC, DCDMH and NCS to make gabapentin lactam in water and with high purity.

Table 1. HPLC purity of gabapentin lactam (**4**)

Entry	Source	HPLC Purity (%)	Single Impurity (RRT, %)		
			0.74	0.84	0.94
1	Example 1 (via N-chloro derivative)	99.75	0.04	0.02	0.09
2	Example 2	98.40	0.05	0.02	ND*
3	Example 3	99.50	0.07	ND*	ND*
4	Example 4	99.43	0.08	0.03	ND*
5	Example 5	98.00	0.22	0.13	ND*

*ND: Not detected

Gabapentin lactam **4** obtained from monoamide **2** and trichloroisocyanuric acid in methanol through the N-chloroamide **3** was converted to gabapentin **1** by following the procedure reported by us in a patent²⁵ (Scheme 3, Table 2). **1** was obtained in 79.5% overall yield from **4**, with more than 99.5% purity and a single unknown impurity <0.05%, matching well with samples obtained by a commercial process using NaOBr for the Hofmann Reaction and was superior to **1** made using NaOCl for the conversion of **4**.²⁶


**Scheme 3** Gabapentin lactam (**4**) to gabapentin (**1**)

Table 2. HPLC purity of gabapentin (**1**) obtained from gabapentin lactam (**4**)

Entry	Source	HPLC Purity (%)	Single Impurity (% ₁ , RRT)	Unknown
1	1 obtained from example 1 gabapentin lactam	99.46	0.0244 (3.7 RRT)	
			0.0094 (0.85 RRT)	
			0.0107 (0.89 RRT)	

CONCLUSIONS

In conclusion, we have developed novel methodologies for the preparation of gabapentin lactam (**4**) in good yield using chlorinating agents such as trichloroisocyanuric acid, sodium dichloroisocyanurate, 1,3-dichloro-5,5-dimethylhydantoin and N-chlorosuccinimide. Recoverability of the precursors, recycling and use of water as solvent make these routes particularly attractive from an environmental point of view. The potential of these reagents for Hofmann Reaction in water with other amides is under study.

EXPERIMENTAL SECTION

General Information: Reactions were monitored by TLC on silica plates using Iodine chamber for visualization. ¹H NMR and ¹³C NMR spectra were recorded in CDCl₃ solvent on 300 MHz NMR spectrometer using TMS as internal reference. Chemical shifts δ and coupling constants J are given in ppm (parts per million) and Hz (hertz) respectively. Chemical shifts are reported relative to residual solvent as an internal standard for ¹H and ¹³C (CDCl₃ δ 7.26 ppm for ¹H and δ 77.0 ppm for ¹³C). The following abbreviations are used to designate signal multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and br = broad. HPLC analyses were performed with Atlantis T-13 column (150 x 4.6 x 3u). Mobile phase:50:50/0.05% formic acid in water:methanol. Column temperature was programmed at 40 °C, with detector wavelength 210 nm. Flow rate was 0.6 mL/min and injection volume was 20 μL. Purity is given as area%. Melting points were recorded on a Veego melting point apparatus and are uncorrected. FT-IR spectrum was recorded using a FTLA 2000 spectrometer. TCCA,

1 NaDCC, DCDMH, NCS, sodium hydroxide, sulphuric acid, hydrochloric acid, toluene, methanol and
2 isopropyl alcohol were of commercial grade and used as such. All compounds are characterized by ¹H
3 NMR and ¹³C NMR. All known compounds data are in consistent with the given literature reports.
4
5
6
7
8

9 Experimental Procedures

10 Example 1: Preparation of gabapentin lactam **4** using N-chloroamide **3**

11
12 (a) Preparation of N-chloroamide **3** from monoamide **2** in methanol: A suspension of monoamide **2** (100
13 g, 0.5025 mol) in methanol (6 V, 600 mL) was heated to 45 - 50 °C and stirred for 0.5 h, when a clear
14 solution resulted. The solution was cooled to 20 - 25 °C, and then treated with TCCA (38.47 g, 0.166
15 mol) in three portions over a period of 45 min under stirring. Reaction mass became turbid during the
16 course of the addition and was stirred for 1 h until TLC showed the disappearance of the starting
17 material **2**. The reaction mixture was then filtered off. The solid obtained was cyanuric acid which was
18 recovered quantitatively. The filtrate was evaporated in vacuo to dryness using a rotovap at 50 °C to get
19 **3** in quantitative yield as a solid. The product was completely characterized by IR, NMR and mass
20 spectral analysis. Melting point: 109 – 111 °C ; IR (ν, cm⁻¹): 3186, 2932, 2854, 1702, 1663, 1453,
21 1397, 1322, 1242, 1191, 1075, 968, 797, 678, 628; ¹H NMR (CDCl₃, 300 MHz): δ 12.00 (s, 1H, -
22 COOH), 9.96 (s, 1H, -CONHCl), 2.43 (s, 2H, -CH₂COOH), 2.39 (s, 2H, -CH₂CONHCl), 1.52-1.27
23 (unresolved multiplet, 10 H, cyclohexyl group); ¹³C NMR (CDCl₃, 75 MHz), δ 172.9 (-COOH), 169.3
24 (-CONHCl), 40.7 (-CH₂COOH), 40.3 (-CH₂CONHCl), 35.1, 35.0, 25.5, 20.9 ppm (cyclohexyl group);
25 HRMS [M+Na]⁺ for C₁₀H₁₆ClNO₃Na calcd, 256.0711; found, 256.07.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 Cyanuric acid which was filtered off was washed with methanol to remove impurities (recovery 100%)
48 and converted to the trichloro derivative by a known procedure²⁷ and reused for a fresh reaction.
49
50
51
52
53

54 (b) Preparation of **4** from **3**: 750 g of 12% sodium hydroxide solution [4.5 equivalents of NaOH with
55 respect to **2** in (a)] was cooled to 0 - 5 °C and treated with **3** (117.3 g, 0.5025 mol) by adding in three
56 portions over a period of 1 h at the same temperature. Reaction was continued at 0 - 5 °C for more 2 h.
57
58
59
60

1 Then temperature of the reaction mass was increased to 15 - 20 °C under continued stirring for two
2 more hours. The temperature was now raised to 50 °C and toluene (2 V, 200 mL) charged in one lot.
3
4 Then the reaction mass temperature was raised to 80 °C and maintained for 8 h. After 8 h of stirring at
5
6 80 °C, the temperature was decreased to 50 °C and the toluene layer separated. The aqueous layer was
7
8 extracted with further amounts of toluene (1 V, 100 mL) and the toluene layer separated. The combined
9
10 toluene layers were washed with 30% brine (100 mL). The toluene solution was evaporated to dryness
11
12 completely using a rotary evaporator under reduced pressure to get gabapentin lactam **4** (69.2 g, 90%)
13
14 as a solid with HPLC purity >99%. The product was identical to standard lactam **4**.¹⁰ Melting point: 89
15
16 – 90 °C (reported: 90 – 91 °C); ¹H NMR (CDCl₃, 300 MHz): δ 6.05 (bs, 1H, -NH), 3.15 (s, 2H, -CH₂-
17
18 NH-), 2.18 (s, 2H, -CH₂CO-), 1.67-1.31 (unresolved m, 10H, cyclohexyl group), ¹³C NMR (CDCl₃, 75
19
20 MHz), δ 178.4 (-NHCO-), 53.8 (-CH₂NH), 43.3 (-CH₂CO-), 39.2, 36.7, 25.6, 22.8 (cyclohexyl group).
21
22
23
24
25
26
27

28 Example 2

29
30 Preparation of **4** from **2** using TCCA in water:

31
32 Monoamide **2** (100 g, 0.5025 mol) and 12% NaOH solution (750 g, 4.4 equivalents of NaOH with
33
34 respect to **2**) were stirred together for 30 min at 25-30 °C. The resulting solution was added to a stirred
35
36 mixture of TCCA (38.47, 0.165 mol) and 150 mL water (1.5 V) at 0 - 5 °C during 1 h. Then the reaction
37
38 mixture was stirred for another 2 h at 0 – 5 °C. The temperature of the reaction mixture was slowly
39
40 raised to 15 - 20 °C and maintained for 2 h. Then the reaction mass temperature was increased to 50 °C
41
42 and toluene (2 V, 200 mL) was charged. The temperature was further raised to 80 °C and maintained for
43
44 8 h. The reaction mass was cooled to 50 °C and the toluene layer separated from the aqueous layer.
45
46
47 Further work up as in example 1 gave **4** (57.6 g, 75%) with HPLC purity >98%.
48
49

50
51 The aqueous solution having a pH of 14 was acidified to pH 2 with 70% H₂SO₄. The precipitated
52
53 cyanuric acid was washed with methanol to remove impurities (recovery 80%) and converted to the
54
55 TCCA by a known procedure²⁷ and reused.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Example 3

Preparation of **4** using NaDCC:

To a solution of NaDCC (60.8 g, 0.276 mol) in 150 mL water (150 mL, 1.5 V with respect to **2**) at 0 - 5 °C was added a solution of **2** (100 g, 0.5025 mol) in 12% NaOH (750 g) at 0 - 5 °C. The reaction was conducted further as in example 2 to yield **4** (65.3 g, 85%) with HPLC purity of 99%.

The aqueous alkaline layer was acidified to pH 2 and the precipitated cyanuric acid filtered off and washed with methanol. The recovered cyanuric acid (80%) was converted to the NaDCC by a known procedure²⁷ and reused.

Example 4

Preparation of **4** using DCDMH:

Hofmann Reaction was conducted on monoamide **2** (100 g) dissolved in 12% sodium hydroxide (750 g) and DCDMH (54.4 g) in water (150 mL) as usual. The solution was heated as before in toluene. **4** was isolated as in example 2 to yield **4** (42.3 g, 55%) with HPLC purity >99%.

Recovery of byproduct dimethylhydantoin was not done because of its high solubility in methanol unlike cyanuric acid.

Example 5

Preparation of **4** using NCS:

Monoamide **2** (100 g in 750 g of 12% sodium hydroxide) was reacted with NCS (73.51 g) in water (150 mL) as usual and the solution processed as earlier in toluene. Evaporation of toluene layer gave **4** (35.7 g, 46%) with HPLC purity >98%.

Recovery of byproduct succinimide was not done because of its high solubility in methanol unlike cyanuric acid.

ACKNOWLEDGMENTS

The authors thank Hikal Ltd management for providing necessary facilities. JVPK is thankful to Dr. R. Sridharan for discussion on this project. Special thanks are extended to the Analytical Department of Hikal Ltd. for providing analytical support.

SUPPORTING INFORMATION

The Supporting Information is available free of charge on the ACS Publications website at DOI:

Characterization (^1H , ^{13}C NMR and HRMS) for compounds **3** & **4** and HPLC chromatograms for compounds **4** & **1** (PDF).

REFERENCES

- (a) Taylor, C. P, *Neurology*. **1994**, *44*, S10-S16. (b) Johnson, D. S.; Lie, J. J. *The art of drug synthesis*, John Wiley & Sons Ltd., 2007. (c) Sutton, K. G.; Snutch, T. P. *Drug Dev. Res.* **2002**, *54*, 167-172. (d) Gee, N. S.; Brown, J. P.; Dissanayake, V. U. K.; Offord, J.; Thurlow, R.; Woodruff, G. N. *J. Biol. Chem.* **1996**, *271*, 5768-5776.
- (a) Jennings, R. A.; Johnson, D. R.; Seamans, R. E.; Zeller, J. R. US Patent US 5319135, 1994. (b) Hartenstein, J.; Satzinger, G.; Herrmann, M.; Heldt, W. US Patent US 4228179, 1980. (c) Gopal, D. US Patent Appl. US 20050148792A1.
- Lagreze, W. A.; Muller-Velten, R.; Feuerstein, T. J. *Grafe's Arch Clin Exp Ophthalmol*, **2001**, *239*, 845-849.
- Henle, F.; Leemhuis, J.; Fischer, C.; Bock, H. H.; Lindemeyer, K.; Feuerstein, T. J.; Meyer, D. K. *J Pharmacol Exp Ther*, **2006**, *319*, 181-191.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
5. Oshima, T.; Duttenhoefer, F.; Xavier, S.; Nelson, K.; Sauerbier, S. *J Oral and Maxillofac Surg*, **2014**, *72*, 485-495.
 6. Sircar, S. S. G. *J. Indian. Chem. Soc.* **1928**, *5*, 549-554.
 7. Geibel, W.; Hartenstein, J.; Herrmann, W.; Witzke, J. US Patent US 5091567, 1992.
 8. Steiner, K.; Herrmann, W.; Crone, G.; Combs, C. S. US Patent US 5068413, 1991.
 9. Yerande, S. G.; Thakur, R. M.; Sharma, S. S.; Gangopadhyay, A. K.; Rupp, H.; Kubavat, H. T.; Nagarajan, K.; Selvan, A.; Nunna, R.; Jalajakshi, V. I. *PCT Int. Appl.* WO2013190357 A1, 2013.
 10. (a) Padaonkar, G.; Thennati, R. Indian Patent IN 186285, 2000. (b) Nagarajan, K.; Sivaramakrishnan, H.; Arulselvan, M.; US Patent US 7632953 B2, 2009.
 11. (a) Bryans, J. S.; Chessum, N. E. A.; Huther, N.; Parsons, A. F.; Ghelfi, F. *Tetrahedron*. **2003**, *59*, 6221-6231. (b) Cagnoli, R.; Ghelfi, F.; Pagnoni, U. M.; Parsons, A. F.; Schenetti, L. *Tetrahedron*. **2003**, *59*, 9951-9960.
 12. (a) Chen, Z.; Chen, Z.; Jiang, Y.; Hu, W. *Synlett*. **2003**, *13*, 1965-1966. (b) Chen, Z.; Chen, Z.; Jiang, Y.; Hu, W. *Tetrahedron*. **2005**, *61*, 1579-1586.
 13. Danieli, B.; Delogu, P.; De Rosa, S.; Fugazza, L. US Patent US 7381823 B2, 2008.
 14. Tilstam, U.; Weinmann.; H. *Org. Process Res. Dev.* **2002**, *6*, 384-393.
 15. (a) Hiegel, G. A.; Hogenauer, T. J.; Lewis, J. C. *Synth. Commun.* **2005**, *35*, 2099-2105. (b) Crane, Z. D.; Nichols, P. J.; Sammakia, T.; Stengel, P. J. *J. Org. Chem.* **2011**, *76*, 277-280.
 16. Pinto, B.; Rohrig, B. *J. Chem. Educ.* **2003**, *80*, 41-44.
 17. Staskun, S. *J. Org. Chem.*, **1988**, *53*, 5287-5291.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
18. Pallavicini, M.; Bolchi, C.; Fumagalli, L.; Piccolo, O.; Valoti, E. *Tetrahedron:Asymmetry*. **2011**, *22*, 379-380.
 19. Gottardi, W. *Monatsh. Chem.* **1967**, *98*, 1613-1617.
 20. (a) Mendonca, G. F.; Sanseverino, A. F.; De Mattos, M. C. S. *Synthesis*. **2003**, 45-48. (b) Mendonca, G. F.; Ramos, R. M.; Esteves, P. M.; De Mattos, M. C. S. *J. Braz. Chem. Soc.* **2005**, *16*, 695-698.
 21. (a) Blomfield, R. A.; Mich, W. US Patent US 2938764, 1960. (b) Rawat, N.; Purdy, D. F.; Engram, M. J. US Patent Appl. US 20080107701, 2008.
 22. Chen, Z.; Zhou, B.; Cai, H.; Zou, X. *Green Chem.* **2009**, *11*, 275-278.
 23. (a) Prakash, G. K. S.; Mathew, T.; Hoole, D.; Esteves, P. M.; Wang, Q.; Rasul, G.; Olah, G. A. *J. Am. Chem. Soc.* **2004**, *126*, 15770-15776. (b) Wu, H.; Hynes, J. Jr. *Org. Lett.* **2010**, *12*, 1192-1195. (c) Du, B.; Jiang, X.; Sun, P. *J. Org. Chem.* **2013**, *78*, 2786-2791. (d) Kalyani, D.; Dick, A. R.; Anani, W. Q.; Sanford, M. S. *Org. Lett.* **2006**, *8*, 2523-2526. (e) Yan, Q.; Luo, J.; Zhang-Negrerie, D.; Li, H.; Qi, X.; Zhao, K.; *J. Org. Chem.* **2011**, *76*, 8690-8697. (f) Chen, C-Y.; Andreani, T.; Li, H. *Org. Lett.* **2011**, *13*, 6300-6303. (g) Halland, N.; Braunton, A.; Bachmann, S.; Marigo, M.; Jorgensen, K. A. *J. Am. Chem. Soc.* **2004**, *126*, 4790-4791.
 24. Toman, J.; Chengzhi, Y.; Weiren, C.; Xiong, L.; Shixiong, D.; Jisheng, B.; Haoxi, Z.; Huo-Sheng, L. T. Chinese Patent CN 103922950A, 2014.
 25. (a) Patel, A.; Tiwari, S. H.; Arulselvan, M.; Shenvi, S. K.; Kumar, P. H.; Gupta, R. P.; Nagarajan, K.; Sankar, L. V. Indian Patent IN 253739, 2012. (b) Nagarajan, K.; Sivaramakrishnan, H.; Arulselvan, M. US Patent US 7635717, 2009.
 26. In our hands, quality of gabapentin obtained using NaOCl did not match with samples obtained by a commercial process using NaOBr for the Hofmann Reaction.

27. Wojtowicz, J. A. *Journal of the Swimming Pool and Spa Industry*. **2001**, 4, 9-16.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60